Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 17 2022 - 07:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of the
Securities
Exchange Act of 1934
For
the month of May 2022
Commission
File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation
of registrant’s name into English)
8
HaSatat St
Modi’in
Israel
7178106
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F
☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
May 17, 2022, Vascular Biogenics Ltd (“VBL”) issued a press release announcing financial results for the first quarter ended
March 31, 2022, which press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K. Also filed as
Exhibits 99.2 and 99.3 to this Report of Foreign Private Issuer on Form 6-K are VBL’s unaudited condensed consolidated interim
financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 and a discussion of its operating and
financial review and prospects for the first quarter ended March 31, 2022.
Exhibits
99.2 and 99.3 to this Report of Foreign Private Issuer on Form 6-K shall be incorporated by reference into VBL’s registration statements
on Form F-3 (File No. 333-251821 and 333-238834), filed with the Securities and Exchange Commission (the “SEC”) on December
30, 2020 and April 19, 2021 , respectively, to the extent not superseded by information subsequently filed or furnished (to the
extent VBL expressly states that it incorporates such furnished information by reference) by VBL under the Securities Act of 1933, as
amended (the “Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
VASCULAR
BIOGENICS LTD. |
|
|
Date:
May 17, 2022 |
By: |
/s/
Dror Harats |
|
Name: |
Dror Harats |
|
Title: |
Chief
Executive Officer |
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2023 to Mar 2024